Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins

Vaccine
Marien I de JongePeter van der Ley

Abstract

The opacity (Opa) proteins of Neisseria meningitidis are outer membrane proteins involved in adhesion and invasion of host epithelial cells and are therefore expected to play an important role in colonisation of the nasopharynx. The majority of meningococcal Opa proteins bind to members of the CEACAM receptor family, such as CEA. Blocking of the Opa-CEACAM interaction by mucosal anti-Opa antibodies could thus constitute an important protective mechanism for novel meningococcal vaccines. In this study we analysed the specific anti-Opa antibody responses after intranasal immunisation of mice with liposomes containing purified and native OpaB (recognising the CEA receptor) and OpaJ (no affinity for CEA) proteins. These antigens were combined with or without one of three different adjuvants, i.e. purified meningococcal LPS, monophosphoryl lipid A (MPL) or the B-subunit of Escherichia coli heat-labile enterotoxin (EtxB). After intranasal immunisation with any of these formulations, anti-Opa IgA antibodies were found in nasal lavages and in some cases anti-Opa IgA and IgG antibodies were also found in lung lavages. With OpaJ but not OpaB, significant bactericidal serum titres were obtained. Of the different adjuvants used, meningococ...Continue Reading

Citations

May 5, 2007·Journal of Molecular Evolution·Ted H M Mes, Jos P M van Putten
Aug 16, 2006·The Journal of Membrane Biology·Fabiana R SantosPietro Ciancaglini
Jan 26, 2016·Critical Reviews in Microbiology·Jennifer L EdwardsKate L Seib
May 13, 2010·Expert Opinion on Drug Delivery·Béatrice HeurtaultFrançoise Pons
Jan 4, 2008·Journal of Drug Targeting·Bram SlütterWim Jiskoot
Oct 20, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Suzanne M BalWim Jiskoot
May 3, 2011·Immunology and Allergy Clinics of North America·Philippe MoingeonLaurent Mascarell
Jan 6, 2009·Advanced Drug Delivery Reviews·Noemi CsabaMaria Jose Alonso
May 17, 2006·Immunology and Allergy Clinics of North America·Laurent MascarellPhilippe Moingeon
Jul 8, 2009·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Li-Ping TsengDer-Zen Liu
Sep 11, 2013·Vaccine·Ann E JerseMichael W Russell
Dec 10, 2016·Human Vaccines & Immunotherapeutics·Helmy Yusuf, Vicky Kett
Apr 4, 2017·Pathogens and Disease·Myron Christodoulides, John Heckels
Mar 3, 2018·Vaccines·Pumtiwitt C McCarthyLaleh Sheikhi Moghaddam
Jun 5, 2007·Expert Review of Vaccines·Maria Leonor Sarno OliveiraPaulo Lee Ho
Oct 22, 2005·Nature Reviews. Immunology·Samir Mitragotri
Oct 11, 2008·Expert Review of Vaccines·Ulrich Baumann
Mar 16, 2019·Frontiers in Immunology·Sunita GulatiPeter A Rice
Jan 28, 2017·Journal of Immunology Research·Valentina BernasconiNils Y Lycke
Sep 10, 2017·Annual Review of Microbiology·Peter A RiceAnn E Jerse
Nov 23, 2018·International Journal of Molecular Sciences·Bijay SinghChong-Su Cho
Nov 5, 2019·Frontiers in Immunology·Michael W RussellScott D Gray-Owen
Sep 16, 2021·Expert Review of Vaccines·Myron ChristodoulidesJohn E Heckels

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.